APR 23, 2018 5:00 AM PDT

UroSEEK: Early Bladder and Urothelial Cancer Urine Screening Test Developed to Complement Urine Cytology

WRITTEN BY: Mauri Brueggeman

Researchers at the Johns Hopkins Kimmel Cancer Center have developed a new gene-based test to detect and monitor cancers involving the bladder and upper urothelial tissues.  They called it UroSEEK which is similar to CancerSEEK, also developed at Johns Hopkins to screen for 8 common cancer types with a single blood test.

UroSEEK information was released in late March 2018 and detects DNA mutations identified in bladder and upper tract urothelial cancers (BC and UTUC respectively).  Prior to this new developed test, urine cytology was the least invasive and standard screening tool but it had limitations.  Voided urine cytology examines cellular morphologic changes which occur in cancerous cells; laboratorians performing the analysis are looking for cellular clumping, high nuclear to cytoplasmic ratio, presence of nucleoli (indicating younger, less mature cells), and other atypical features indicating a potential disease process.  There are some reports that urine cytology can very accurately diagnose high grade carcinoma and bladder cancer in situ.

There are challenges to this standard test/screen option, including:

  • Employment and retention of skilled cytologists and cytopathologists to perform analysis

  • Low sensitivity due to tumor differences and tumor grade – high grade tumors with distinct and high degree of morphological change will be identified more accurately and more consistently; lower grade or early tumorigenesis (low grade BC and UTUCs) is difficult, if not impossible, to detect

  • Specimen quality and quantity

UroSEEK tests for DNA changes commonly associated with BC and UTUC, which can both present challenges for early diagnosis.  UroSEEK has three components and aims not to replace urine cytology but complement it to improve sensitivity and early disease detection.  The first, is to detect mutations in the regions of 10 genes consistently found to be mutated in urothelial tumors: FGFR3, TP53, CDKN2A, ERBB2, HRAS, KRAS, PIK3CA, MET, VHL, and MLL.  Some of these may sound familiar; they are involved in additional oncogenic pathways in other cancers across multiple tissues and locations.  The second component detects the mutation of an oncogenic promoter called TERT.  Lastly, the test acts to detect aneuploidy (presence of abnormal number of chromosomes in a cell).  These three factors are known to contribute to these types of cancers. 

The testing method involves the use of three separate assays.  Multiplex PCR for the first 10 gene analysis, singleplex PCR for the TERT promoter gene examination, and PCR to co-amplify L1 retrotransposon repeats, known as LINEs, which are known to be on all 39 acrocentric autosomal chromosome arms as published in 2012 in PLoS One

This approach is a valuable use of technology and diagnostic combination to help improve patient care and outcomes.  Questions to further consider will be the feasibility of offering this test in healthcare systems or institutions that don’t have large reference laboratory or molecular diagnostic lab capabilities.  In addition, from the provider and insurance perspective, often insurers will allow only certain approved standard testing for screening purposes.  How long will it take for agreement and policy changes to be implemented to allow for this type of testing to be “part” of the screening standard rather than a “compliment” which some may determine is not necessary.  This impacts the patient and billing practices of the laboratory and institution, which could greatly affect the likelihood of its use or implementation.

 

Sources: Elife Journal, Oncology Times, Medscape, PLos One,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
DEC 02, 2019
Cancer
DEC 02, 2019
What patients don't know: the side effects of cancer treatment
If anyone you know has ever had to go through treatment for cancer, or if you yourself have had to, you know that fighting the cancer is only part of the b...
JAN 22, 2020
Cancer
JAN 22, 2020
How the VISTA molecule affects immune responses
A new study describes how a molecule named VISTA has been impeding immune responses in cancer therapies. By turning this molecule “off,” resear...
JAN 23, 2020
Cancer
JAN 23, 2020
The role of circular RNA in melanoma
New research published in the journal Cancer Cell investigates the role of circular RNAs in the spread of melanoma. Melanoma is a particularly aggressive c...
JAN 27, 2020
Genetics & Genomics
JAN 27, 2020
Finding Cancer-Promoting Genes Using Machine Learning
Machine learning algorithms are increasingly being applied to the vast amount of genetic data that has been generated over the past decade....
FEB 01, 2020
Cancer
FEB 01, 2020
How does infrared light affect our skin?
New research published recently in The FASEB Journal reports, at last, the effects of visible and infrared light on our skin. According to the study, UV, v...
FEB 21, 2020
Cancer
FEB 21, 2020
Understanding cancer heterogeneity
A team of researchers from Cornell has taken an innovative approach to crack the diversity code of cancer cells. Using a statistical modeling technique mor...
Loading Comments...